• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Acumen (organization)

    46论文总数
    1,101引用总数

    Acumen (formerly known as Acumen Fund) is a nonprofit impact investment fund focused on investing in social enterprises that serve low-income individuals in United States. It aims to demonstrate that small amounts of philanthropic capital, combined with business acumen can result in thriving enterprises that serve vast numbers of the poor. Over the years, Acumen has invested $115 million in 113 companies and has had a successful track record in sourcing and executing investment opportunities in the clean energy, health care and agriculture sectors.

    论文量&引用量时间轴

    机构学者

    论文(46)

    年份
    起
    –
    止
    排序
    1Safety Monitoring of Multiple Health Outcomes Following 2023-2024 COVID-19 Vaccination among Commercial Health Plan Enrollees Aged 6 Months-64 Years in the United States
    Carla E. Zelaya, Michelle Ondari, Joann F. Gruber, Chunyi Xia, Daniel C. C. Beachler, Djeneba Audrey Djibo,Kandace L. Amend, Fengdi Zhang,Alex Secora, Xi Wang, Madhuri Palnati, Jessica Rose R. Hervol,
    2025PHARMACOEPIDEMIOLOGY AND DRUG SAFETY(2025)
    引用
    AI阅读
    加入学术空间
    2The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease
    Steven T Bird,Kate Gelperin,Elizabeth R Smith,Tae Hyun Jung,Hai Lyu,Aliza Thompson, Olivia Easley, Kushal B Naik,Yueqin Zhao, Rekha Kambhampati,Michael Wernecke, Ali Niak,

    BACKGROUND:There is a paucity of data on treatment of osteoporosis in patients with advanced chronic kidney disease (CKD). OBJECTIVE:To assess the risk for emergently treated hypocalcemia with denosumab by stage of CKD and presence of CKD-mineral and bone disorder (CKD-MBD). DESIGN:Target trial emulation. SETTING:Medicare fee-for-service data with prescription drug coverage, 2012 to 2020. PARTICIPANTS:Female patients aged 65 years or older initiating denosumab, oral bisphosphonates, or intravenous (IV) bisphosphonates for osteoporosis. MEASUREMENTS:Hospital and emergency department admissions (that is, emergent care) for hypocalcemia were assessed in the first 12 treatment weeks. Inverse probability of treatment weighted cumulative incidence and weighted risk differences (RDs) were calculated. RESULTS:A total of 361 453 patients treated with denosumab, 829 044 treated with oral bisphosphonates, and 160 413 treated with IV bisphosphonates were identified. Risk for emergently treated hypocalcemia with denosumab versus oral bisphosphonates increased with worsening CKD stage (P < 0.001), with greatest risk among dialysis-dependent (DD) patients (3.01% vs. 0.00%; RD, 3.01% [95% CI, 2.27% to 3.77%]) and non-dialysis-dependent (NDD) patients with CKD stages 4 and 5 (0.57% vs. 0.03%; RD, 0.54% [CI, 0.41% to 0.68%]). Among patients with stages 4 and 5 CKD (NDD + DD), denosumab had a greater risk for emergently treated hypocalcemia versus oral bisphosphonates in those with CKD-MBD (1.53% vs. 0.02%; RD, 1.51% [CI, 1.21% to 1.78%]) than in those without CKD-MBD (0.22% vs. 0.03%; RD, 0.19% [CI, 0.08% to 0.31%]). Denosumab also showed increased risk compared with IV bisphosphonates. LIMITATION:Generalizability to men and non-Medicare populations. CONCLUSION:Risk for emergently treated hypocalcemia with denosumab increased with worsening CKD stage and was highest in DD patients and those with CKD-MBD. PRIMARY FUNDING SOURCE:U.S. Food and Drug Administration.

    2024Annals of internal medicine(2024)引用:9
    引用
    AI阅读
    加入学术空间
    3Linkage of Mother and Infant Records Using Commercial Claims Data Within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative
    Carla E. Zelaya, Joann F. Gruber,Zhiruo Wan,Yoganand Chillarige,Sylvia Cho, Mao I. Hu, Patricia C. Lloyd, Ramya Avula, Ruobing Lyu,Elizabeth J. Bell, Djeneba Audrey Djibo,Tainya C. Clarke,
    2024PHARMACOEPIDEMIOLOGY AND DRUG SAFETY(2024)
    引用
    AI阅读
    加入学术空间
    4Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years
    Mao Hu,Hui Lee Wong,Yuhui Feng,Patricia C Lloyd,Elizabeth R Smith,Kandace L Amend,Annemarie Kline,Daniel C Beachler,Joann F Gruber,Mahasweta Mitra,John D Seeger,Charlalynn Harris,

    Importance:Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective:To conduct near-real-time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years. Design, Setting, and Participants:This population-based study was conducted under a public health surveillance mandate from the US Food and Drug Administration. Participants aged 5 to 17 years were included if they received BNT162b2 COVID-19 vaccination through mid 2022 and had continuous enrollment in a medical health insurance plan from the start of an outcome-specific clean window until the COVID-19 vaccination. Surveillance of 20 prespecified health outcomes was conducted in near real time within a cohort of vaccinated individuals from the earliest Emergency Use Authorization date for the BNT162b2 vaccination (December 11, 2020) and was expanded as more pediatric age groups received authorization through May and June 2022. All 20 health outcomes were monitored descriptively, 13 of which additionally underwent sequential testing. For these 13 health outcomes, the increased risk of each outcome after vaccination was compared with a historical baseline with adjustments for repeated looks at the data as well as a claims processing delay. A sequential testing approach was used, which declared a safety signal when the log likelihood ratio comparing the observed rate ratio against the null hypothesis exceeded a critical value. Exposure:Exposure was defined as receipt of a BNT162b2 COVID-19 vaccine dose. The primary analysis assessed primary series doses together (dose 1 + dose 2), and dose-specific secondary analyses were conducted. Follow-up time was censored for death, disenrollment, end of the outcome-specific risk window, end of the study period, or a receipt of a subsequent vaccine dose. Main Outcomes:Twenty prespecified health outcomes: 13 were assessed using sequential testing and 7 were monitored descriptively because of a lack of historical comparator data. Results:This study included 3 017 352 enrollees aged 5 to 17 years. Of the enrollees across all 3 databases, 1 510 817 (50.1%) were males, 1 506 499 (49.9%) were females, and 2 867 436 (95.0%) lived in an urban area. In the primary sequential analyses, a safety signal was observed only for myocarditis or pericarditis after primary series vaccination with BNT162b2 in the age group 12 to 17 years across all 3 databases. No safety signals were observed for the 12 other outcomes assessed using sequential testing. Conclusions and Relevance:Among 20 health outcomes that were monitored in near real time, a safety signal was identified for only myocarditis or pericarditis. Consistent with other published reports, these results provide additional evidence that COVID-19 vaccines are safe in children.

    2023JAMA pediatrics(2023)引用:20
    引用
    AI阅读
    加入学术空间
    5Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies.
    Karen L. Schneider,Elizabeth J. Bell, C. K. Zhou,Grace Yang,Patricia Lloyd,Tainya C. Clarke,Michael Wilkinson, Emily E. Myers,Kandace L. Amend,John D. Seeger,Yoganand Chillarige,Richard A. Forshee,

    IMPORTANCE Safety and effectiveness studies of COVID-19 vaccines are being conducted using clinical data, including administrative claims. However, claims data only partially capture administered COVID-19 vaccine doses for numerous reasons, such as vaccination at sites that do not generate claims for reimbursement. OBJECTIVE To evaluate the extent to which Immunization Information Systems (IIS) data linked to claims data enhances claims-based COVID-19 vaccine capture for a commercially insured population and to estimate the magnitude of misclassification of vaccinated individuals as having unvaccinated status in the linked IIS and claims data. DESIGN, SETTING, AND PARTICIPANTS This cohort study used claims data from a commercial health insurance database and obtained vaccination data from IIS repositories in 11 US states. Participants were individuals younger than 65 years who resided in 1 of 11 states of interest and who were insured in health plans from December 1, 2020, through December 31, 2021. MAIN OUTCOMES AND MEASURES Estimated proportion of individuals with at least 1 dose of any COVID-19 vaccine and proportion of individuals with a completed vaccine series based on general population guidelines. Vaccination status estimates were calculated and compared using claims data alone and linked IIS and claims data. Remaining misclassification of vaccination status was assessed by comparing linked IIS and claims data estimates with estimates from external surveillance data sources (Centers for Disease Control and Prevention [CDC] and state Department of Health [DOH]) and capture-recapture analysis. RESULTS This cohort study included 5 112 722 individuals (mean [SD] age, 33.5 [17.6] years; 2 618 098 females [51.2%]) from 11 states. Characteristics of those who received at least 1 vaccine dose and those who completed a vaccine series were similar to the overall study population. The proportion with at least 1 vaccine dose increased from 32.8% using claims data alone to 48.1% when the datawere supplemented with IIS vaccination records. Vaccination estimates using linked IIS and claims data varied widely by state. The percentage of individuals who completed a vaccine series increased from 24.4% to 41.9% after the addition of IIS vaccine records and varied across states. The percentages of underrecording using linked IIS and claims datawere 12.1% to 47.1% lower than those using CDC data, 9.1% to 46.9% lower than the state DOH, and 9.2% to 50.9% lower than capturerecapture analysis. CONCLUSION AND RELEVANCE Results of this study suggested that supplementing COVID-19 claims records with IIS vaccination records substantially increased the number of individuals who were identified as vaccinated, yet potential underrecording remained. Improvements in reporting vaccination data to IIS infrastructures could allow frequent updates of vaccination status for all individuals and all vaccines.

    2023JAMA Network Open(2023)引用:11
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 46 篇论文

    合作机构(44)

    美国食品药品管理局合作论文 9
    宾夕法尼亚大学合作论文 8
    Centers for Medicare & Medicaid Services合作论文 6
    美国卫生与公众服务部合作论文 5
    IQVIA Inc.合作论文 4
    罗伯特戈登大学合作论文 2
    约翰·开普勒林茨大学合作论文 1
    Massachusetts General Hospital,Harvard Medical School合作论文 1
    American Physical Therapy Association合作论文 1
    加州大学圣塔巴巴拉分校合作论文 1

    机构统计